Early research (Phase 1)Study completedNCT04987333What this trial is testingStudy of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian ParticipantsWho this might be right forInflammatory Diseases Amgen 32
Testing effectiveness (Phase 2)Study completedNCT02406651What this trial is testingStudy of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHDWho this might be right forAcute Graft vs Host Disease EVIVE Biotechnology 30
Not applicableAvailableNCT04768907What this trial is testingEarly Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host DiseaseWho this might be right forAcute Graft Versus Host Disease in IntestineSteroid Refractory GVHD MaaT Pharma
Large-scale testing (Phase 3)UnknownNCT02506231What this trial is testingThe Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation OutcomeWho this might be right forGraft vs Host DiseaseAllogeneic Hematopoietic Cell TransplantationMucositis Rabin Medical Center 160
Post-approval studies (Phase 4)Study completedNCT02156570What this trial is testingDAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral)Who this might be right forHepatitis C Kirby Institute 20
Testing effectiveness (Phase 2)Ended earlyNCT00964665What this trial is testingPharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection SubjectsWho this might be right forChronic Hepatitis B Novartis Pharmaceuticals 141
Post-approval studies (Phase 4)Study completedNCT00537537What this trial is testingTo Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB)Who this might be right forHepatitis B, Chronic Novartis Pharmaceuticals 100